Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial.
- Resource Type
- Article
- Authors
- Ou, Jianjun; Smith, Robert C.; Tobe, Russell H.; Lin, Jingjing; Arriaza, Jen; Fahey, Jed W.; Liu, Ruiting; Zeng, Ying; Liu, Yanan; Huang, Lian; Shen, Yidong; Li, Yamin; Cheng, Daomeng; Cornblatt, Brian; Davis, John M.; Zhao, Jingping, ; Wu, Renrong, ; Jin, Hua,
- Source
- Journal of Autism & Developmental Disorders; Feb2024, Vol. 54 Issue 2, p628-641, 14p
- Subject
- Caregiver attitudes
Child behavior
Behavior
Autism
Evaluation
Children
Sulfur compounds
Drug efficacy
Drug tolerance
Age distribution
Attitudes of medical personnel
Randomized controlled trials
Placebos
Blind experiment
Research funding
Antipsychotic agents
China
- Language
- ISSN
- 01623257
Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. [ABSTRACT FROM AUTHOR]